What does a positive hepatitis B core antibody (anti‑HBc) indicate, what is its significance for patients initiating biologic therapy, and should such patients receive hepatitis B vaccination?

Hepatitis B Core Antibody (Anti-HBc) Positive: Significance and Management in Biologic Therapy

A positive anti-HBc indicates past or current HBV infection, and patients starting biologic therapy with positive anti-HBc require either antiviral prophylaxis or close monitoring depending on their HBsAg status and type of therapy—vaccination is NOT indicated for anti-HBc positive patients as they have already been exposed to HBV. 1

What Anti-HBc Positivity Indicates

Anti-HBc (hepatitis B core antibody) appears early in HBV infection and typically persists for life 2, 3. The interpretation depends on accompanying serologic markers:

• HBsAg negative + anti-HBc positive = Past HBV infection (resolved or occult infection) 1
• HBsAg positive + anti-HBc positive = Chronic HBV infection 1
• Anti-HBc alone (isolated) = May represent false-positive, past exposure with resolved infection, or rarely occult chronic infection 2

The presence of anti-HBs alongside anti-HBc indicates natural immunity from resolved infection, while anti-HBc without anti-HBs suggests isolated core antibody positivity 4, 5.

Critical Significance Before Biologic Therapy

Mandatory Screening Protocol

All patients anticipating biologic therapy must be tested with three markers: HBsAg, anti-HBc (total Ig or IgG), and anti-HBs before starting treatment. 1 This is a strong recommendation based on the high risk of HBV reactivation, which can lead to fulminant hepatic failure and death 4, 6.

Risk Stratification by Serologic Status

For HBsAg-positive patients (chronic HBV):

• Start antiviral prophylaxis immediately with high-barrier agents (entecavir, tenofovir disoproxil fumarate [TDF], or tenofovir alafenamide [TAF]) 1
• Continue prophylaxis during therapy and for at least 12 months after completion 1
• Monitor HBV DNA and ALT at baseline and every 6 months 1

For HBsAg-negative but anti-HBc positive patients (past HBV):

The management differs critically based on the type of biologic therapy:

• High-risk therapies (anti-CD20 antibodies like rituximab, stem cell transplantation):

  • Require antiviral prophylaxis with entecavir, TDF, or TAF 1, 7
  • Continue for at least 12 months after therapy completion (18 months for rituximab-based regimens) 1
  • Reactivation rates: 3-45% without prophylaxis 4, 6

• Other biologic therapies (anti-TNF, other immunosuppressants):

  • Two acceptable strategies 1:
    1. Monitoring approach: Check HBsAg and ALT every 3 months during therapy and up to 12 months after; start immediate antiviral therapy if HBsAg becomes positive
    2. Prophylactic approach: Preemptive antiviral therapy (preferred if adherence to frequent monitoring is uncertain)

Common Pitfall to Avoid

Do not delay anticancer or biologic therapy while awaiting HBV test results or specialist consultation 1. Screening should be done before or at treatment initiation, but therapy should proceed as planned.

Vaccination Status: NOT Indicated for Anti-HBc Positive Patients

Patients who are anti-HBc positive should NOT receive HBV vaccination because they have already been exposed to HBV 2, 3. The anti-HBc marker persists for life after natural infection and indicates prior viral exposure.

Vaccination is only appropriate for:

• Patients negative for all three markers (HBsAg, anti-HBc, anti-HBs) 2, 8
• HBV-naïve patients with hematologic malignancies before starting immunosuppressive therapy 7

Key distinction: Vaccinated individuals show anti-HBs positive but anti-HBc negative, while naturally immune individuals (past infection) show both anti-HBs and anti-HBc positive 2, 3, 5.

Special Consideration for Isolated Anti-HBc

In rare cases of isolated anti-HBc positivity (without HBsAg or anti-HBs), this may represent:

• False-positive result (25-47% of cases) 9, 10, 11
• Resolved infection with waning anti-HBs 2
• Occult HBV infection (check HBV DNA if suspected) 4

For these patients starting biologic therapy, treat as past HBV infection and follow monitoring/prophylaxis protocols above rather than vaccinating 1.

Practical Management Algorithm

1. Screen all patients with HBsAg, anti-HBc, and anti-HBs before biologic therapy 1
2. If HBsAg positive: Start antiviral prophylaxis immediately 1
3. If HBsAg negative but anti-HBc positive:
   • Anti-CD20 therapy or transplant → Start prophylaxis 1, 7
   • Other biologics → Monitor every 3 months OR give prophylaxis 1
4. If all markers negative: Consider vaccination before starting therapy 7
5. Never vaccinate anti-HBc positive patients 2, 3

The evidence strongly supports universal screening and risk-stratified management to prevent potentially fatal HBV reactivation 1, 4, 1.